Immunotherapy and More: The Top 10 Posts of 2017
While Cancer Research Catalyst covers the spectrum of cancer research news, we weren’t surprised to discover that the hottest topic on the blog this past year was immunotherapy.
It was certainly an exciting year for immunotherapy. In May, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for use based on the presence of certain biomarkers rather than the site of origin of the tumor. Later in the year, the FDA approved two types of chimeric antigen receptor (CAR) T-cell therapy. Several immunotherapeutics received expanded approval, allowing patients with more types of cancer access to these potentially lifesaving treatments.
However, researchers are still striving to learn more about immunotherapy, exploring potential combination therapies and seeking biomarkers to predict which patients are the most likely to benefit from these treatments. That quest was at the heart of several of our most popular blog posts in 2017.
We’d love to know what you’d like to read more of in 2018. In the meantime, here are the Top 10 Cancer Research Catalyst blog posts of 2017, based on the number of page views: